MADE POSSIBLE BY:
MADE POSSIBLE BY:

Study Demonstrates that Targeting EphA3 Expressing Tumor Stem Cells and Neovasculature is a Viable...

The Eph type-A receptor 3 (also known as EphA3 receptor) is recognized as a functional tumor-specific therapeutic target in glioblastoma (GBM) and is significantly elevated in recurrent disease. EphA3 is recognized for has maintaining...

CytomX Therapeutics Acquires Technologies Developed by Agensys

Clinical-stage and oncology-focused biopharmaceutical company CytomX Therapeutics, pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, has acquired drug-conjugate linker-toxin and CD3-based bispecific technologies from Agensys, an affiliate...

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine in Patients with...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being developed by ADC Therapeutics, for the treatment of patients with...

Mersana Therapeutics Licenses GlycoConnect™ Site-Specific ADC Technology from Synaffix

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet need, and  Synaffix, a Dutch biotechnology company, have entered into...

Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC Candidate Targeting NaPi2b

Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need, confirmed that, after a strategic evaluation, the company and its...

Novel Payloads for Antibody-drug Conjugates

The development of antibody-drug conjugates or ADCs, has resulted in the need of developing novel compounds that can be used as payloads. Enediynes, represented by are two different classes of antitumor compounds, including the nine-membered...

Novel Method to Quickly Develop Site Specific ADCs

Scientists at William Marsh Rice University, commonly known as Rice University, a private research university located in Houston, Texas, United States, have found a simple method to attach drugs or other substances to antibodies,...

Bio-Thera Solutions Files IND for BAT8003 as Potential Treatment for Trop2 Positive Cancers

China-based Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, has filed an Investigational New Drug Application (IND) with the China National Medical Products Administration (NMPA)...

Oxford Bio Receives US Investigational New Drug Clearance for OBT076

The U.S Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for OBT076, an experimental antibody-drug conjugate or ADC being developed by  Oxford BioTherapeutics for the treatment of women with high...

MabPlex Opens New Phase III and Commercial Manufacturing Facility

MabPlex International, a fully integrated Contract Development and Manufacturing Organization (CDMO) with sites in China and the United States, has inaugurated their new manufacturing facility in Yantai, Shandong, China. The grand opening and ribbon-cutting ceremony...